['1 NC DENOTES A MEAN CHANGE OF LESS THAN 10%', '2 PEDIATRICS', '3 MEAN INCREASE IN ADULTS AT HIGH DOSES OF IMMEDIATE-RELEASE OXCARBAZEPINE', 'AED COADMINISTERED (DAILY DOSE)', 'IR- OXCARBAZEPINE (DAILY DOSE)', 'INFLUENCE OF IR- OXCARBAZEPINE ON AED CONCENTRATION MEAN CHANGE [90% CONFIDENCE INTERVAL]', 'INFLUENCE OF AED ON MHD CONCENTRATION (MEAN CHANGE, 90% CONFIDENCE INTERVAL)', 'RECOMMENDATION', 'CARBAMAZEPINE (400 \xe2\x80\x93 2000 MG)', '900 MG', 'NC 1', '40% DECREASE [CI: 17% DECREASE, 57% DECREASE]', 'CONSIDER INITIATING OXTELLAR XR\xe2\x84\xa2 AT A HIGHER DOSE. MONITOR AND TITRATE DOSE TO DESIRED CLINICAL EFFECT (SEE 2.6 )', 'PHENOBARBITAL (100 \xe2\x80\x93 150 MG)', '600 \xe2\x80\x93 1800 MG', '14% INCREASE [CI: 2% INCREASE, 24% INCREASE]', '25% DECREASE [CI: 12% DECREASE, 51% DECREASE]', 'PHENYTOIN (250 \xe2\x80\x93 500 MG)', '600 \xe2\x80\x93 1800 >1200-2400', 'NC 1,2 UP TO 40% INCREASE 3 [CI: 12% INCREASE, 60% INCREASE]', '30% DECREASE [CI: 3% DECREASE, 48% DECREASE]', 'VALPROIC ACID (400 \xe2\x80\x93 2800 MG)', '600-1800', 'NC 1', '18% DECREASE [CI: 13% DECREASE, 40% DECREASE]', 'MONITOR. DOSE ADJUSTMENT OF OXTELLAR XR\xe2\x84\xa2 MAY NOT BE NEEDED.']